"The FDA approval for the study is anticipated this year. The trial will be a randomised non-inferiority study between standard of care (existing TAVR devices) and DurAVR™ THV."
Wayne Paterson
So this study involved implanting different brands of valves alongside ours. Can someone explain why we do this? Can't we just compare our results with previous results (from other valves)?
- Forums
- ASX - By Stock
- AVR
- Ann: Annual Report to shareholders
Ann: Annual Report to shareholders, page-8
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.00 |
Change
0.020(0.11%) |
Mkt cap ! $364.8M |
Open | High | Low | Value | Volume |
$19.00 | $19.00 | $19.00 | $1.007K | 53 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 843 | $18.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.99 | 212 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 843 | 18.520 |
2 | 55 | 18.510 |
2 | 1029 | 18.500 |
1 | 50 | 18.400 |
1 | 273 | 18.250 |
Price($) | Vol. | No. |
---|---|---|
18.990 | 212 | 1 |
19.000 | 210 | 1 |
19.200 | 150 | 1 |
19.500 | 1230 | 1 |
19.800 | 1055 | 2 |
Last trade - 10.00am 30/05/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online